Omeros reported $-37438000 in EBIT for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebit Change
Acelrx Pharmaceuticals ACRX:US $ -8672000 323K
Aerie Pharmaceuticals AERI:US $ -18137000 15.51M
Alnylam Pharmaceuticals ALNY:US $ -191686000 44.95M
Biomarin Pharmaceutical BMRN:US $ 39.15M 9.82M
Cytokinetics CYTK:US $ -10874000 66.98M
Dynavax Technologies DVAX:US $ 127.67M 96.2M
Gilead Sciences GILD:US $ 2029M 868M
Insmed INSM:US $ -100938000 513K
Intercept Pharmaceuticals ICPT:US $ -13363000 3.09M
Knight Therapeutics Inc GUD:CN C$ 2.34M 2.65M
Macrogenics MGNX:US $ -41808000 24.83M
Mirati Therapeutics MRTX:US $ -177205000 7.01M
Omeros OMER:US $ -37438000 2.39M
Pacira Pharmaceuticals PCRX:US $ 13.18M 8.55M
Pfizer PFE:US $ 12099M 2104M
Sangamo Biosciences SGMO:US $ -45734000 473K
Sarepta Therapeutics SRPT:US $ -211132000 124.25M
United Therapeutics UTHR:US $ 201.8M 86.2M
Vertex Pharmaceuticals VRTX:US $ 1119.3M 85.9M
Vital Therapies VTL:US $ -20610000 825K
Xoma XOMA:US $ -4767000 2.7M